Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Hensen

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Clinical & Translational Immunology|March 8, 2021
Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody featuresLouise C Rowntree, Brendon Y Chua, Suellen Nicholson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2020
Suboptimal SARS-CoV-2-specific CD8<sup>+</sup> T cell response associated with the prominent HLA-A*02:01 phenotypeJennifer R Habel, Thi H O Nguyen, Carolien E van de Sandt, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2021
Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous AustraliansLuca Hensen, Thi H O Nguyen, Louise C Rowntree, et al.
Nature Medicine|February 18, 2022
Influenza virus infection history shapes antibody responses to influenza vaccinationMaria Auladell, Hoang Vu Mai Phuong, Le Thi Quynh Mai, et al.
Research Square|August 31, 2021
Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severityWuji Zhang, Brendon Chua, Kevin Selva, et al.
Cell|October 30, 2024
An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of OceaniaLiyen Loh, Philippa M Saunders, Camilla Faoro, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Nature Communications|May 12, 2021
Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patientsThi H O Nguyen, Marios Koutsakos, Carolien E van de Sandt, et al.
Nature Communications|May 19, 2021
CD8<sup>+</sup> T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorphLuca Hensen, Patricia T Illing, E Bridie Clemens, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Clinical & Translational Immunology|March 8, 2021
Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody featuresLouise C Rowntree, Brendon Y Chua, Suellen Nicholson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2020
Suboptimal SARS-CoV-2-specific CD8<sup>+</sup> T cell response associated with the prominent HLA-A*02:01 phenotypeJennifer R Habel, Thi H O Nguyen, Carolien E van de Sandt, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2021
Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous AustraliansLuca Hensen, Thi H O Nguyen, Louise C Rowntree, et al.
Nature Medicine|February 18, 2022
Influenza virus infection history shapes antibody responses to influenza vaccinationMaria Auladell, Hoang Vu Mai Phuong, Le Thi Quynh Mai, et al.
Research Square|August 31, 2021
Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severityWuji Zhang, Brendon Chua, Kevin Selva, et al.
Cell|October 30, 2024
An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of OceaniaLiyen Loh, Philippa M Saunders, Camilla Faoro, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Nature Communications|May 12, 2021
Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patientsThi H O Nguyen, Marios Koutsakos, Carolien E van de Sandt, et al.
Nature Communications|May 19, 2021
CD8<sup>+</sup> T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorphLuca Hensen, Patricia T Illing, E Bridie Clemens, et al.
Pageof 4